Abstract:e21577 Background: Melanoma in China has unique characteristics, especially compared with those in euramerican white race. In european and american countries, nearly 90% of melanoma patients are cutaneous melanoma; while 60% of melanoma in China are acral melanoma, accompanied with a considerable proportion of mucosal melanoma. Mapping the mutation landscape of melanoma in China can provide an important basis for targeted therapy of melanoma patients. Methods: Tissue samples from 223 patients with melanoma were sequenced using multi-gene NGS panel Onco PanScan to detect somatic mutations in melanoma. Results: As a result, BRAF (24.2%) and NRAS (15.7%) were the top two most mutated driver genes. In BRAF, V600E was the most common mutation, which accounted for 80% of all BRAF mutations. And Q61R/K was the most common mutation in NRAS, which accounted for 68.6% of all NRAS mutations. As to CNVs, the most frequently amplified genes were CCND1 (23, 10.3%), CDK4 (18, 8.1%), MDM2 (17, 7.6%), FGF19 (16, 7.2%), FGF4 (13, 5.8%), FGF3 (12, 5.4%), KIT (12, 5.4%), RICTOR (12, 5.4%). At the same time, a small number of EGFR, HER2, MET, MYC amplifications were detected. Interestingly, a considerable proportion of CNVs were related with hyperprogressive disease, including amplification of MDM2, CCND1, FGF3, FGF4, FGF19. Except for SNVs and CNVs, 16 gene fusions were detected in 13 samples (5.8%), among which the frequency of fusions involving BRAF, ALK, RAF1 was 2.2% (5/223), 1.3% (3/223) and 1% (2/223) respectively. Among these 16 fusions, only 4 fusions (AGAP3-BRAF, GTF2I-BRAF, TPM3-ALK, DCTN1-ALK) were reported previously, leaving the remaining 12 fusions new detected. As was reported, AGAP3-BRAF fusion was the mechanism by which melanoma patients with BRAF V600E mutations developed resistance to vemurafenib; GTF2I-BRAF fusion mediated the activation of MAPK pathway in fibrous astrocytoma. At last, we also compared the frequency of fusion detected in driver-positive and driver-negative melanoma (no somatic mutations detected in BRAF, HRAS, KRAS, NRAS, NF1, KIT, GNAQ, GNA11), and the result showed the frequency of fusion detected in driver-negative melanoma was significantly higher (9/78, 11.5% vs. 4/145, 2.8%). Conclusions: Through DNA-based NGS, the mutation landscape of Chinese melanoma patients was depicted. BRAF was the most frequently mutated driver gene with the main mutation type of V600E (19.7%) which was significantly lower than that of white race in TCGA-SKCM database (44.2%). On the other hand, DNA-based NGS can detect potentially druggable fusions, and compared with driver positive melanoma patients, fusions were enriched in patients with no driver mutations detected. Perhaps for driver negative melanoma patients, RNA-based NGS should be used to detect more potential druggable fusions which would bring clinical benefit.

Real-world Data in Clinically Non-Small Cell Lung Cancer (NSCLC) with Chinese Population Harboring BRAF Gene Fusions: A Multicenter Study.

Identification Of Frequent Braf Copy Number Gain And Alterations Of Raf Genes In Chinese Prostate Cancer

P2.03-09 the Real World of NTRK Fusion Data in the Chinese Lung Cancer Populations: A Multicenter Study

The analysis of BRAF fusions characteristics in Chinese solid tumor patients.

Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma

BRAF fusion in lung cancer.

P2.16-08 Clinical Characteristics and Outcomes of Patients with BRAF Mutated Non-Small Cell Lung Cancer

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

Truncation Of Braf And Raf1 In Prostate Cancer In China

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients with the BRAF-V600E Mutation

Co-mutations of Epidermal Growth Factor Receptor and BRAF in Chinese Non-Small Cell Lung Cancer Patients

Incidence of FGFR-TACC Gene Fusions in Chinese Non-Small Cell Lung Cancer (NSCLC): A Multicenter Study.

23P Genomic Profiling of Gene Aberrations in 323 Chinese NSCLC Patients

Analysis of genomic alterations in pan-cancer from a large real-world Chinese population.

BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center

Comprehensive Genomic Profiling in Chinese Patients with Clear Cell Renal Cell Carcinoma.

P1.02-056 BRAF Non-V600E Mutations Recurrently Found in Non-Small Cell Lung Cancer in Chinese Patients

Prevalence of BRAF V600E Mutation in Chinese Melanoma Patients: Large Scale Analysis of BRAF and NRAS Mutations in a 432-Case Cohort.

Genetic landscape of melanoma in China reveals enrichment of fusions in driver-negative melanoma.

Clinical Significance of BRAFV600E Mutation in Circulating Tumor DNA in Chinese Patients with Melanoma